Mechanisms of bone anabolism regulated by statins

Autor: Feng Ruan, Qiang Zheng, Jinfu Wang
Rok vydání: 2012
Předmět:
Anabolism
Common disease
Osteoporosis
lcsh:Life
lcsh:QR1-502
MKP-1
MAPK phosphatase-1

Osteoclasts
Review Article
BMSC
bone-marrow-derived mesenchymal stem cell

Disease
Bioinformatics
Biochemistry
lcsh:Microbiology
FPP
farnesyl pyrophosphate

TGFβ
transforming growth factor β

TRAF
tumour-necrosis-factor-receptor-associated factor

OVX
ovariectomized

HMG-CoA
3-hydroxy-3-methylglutaryl-CoA

mesenchymal stem cell (MSC)
apoptosis
Osteoblast
medicine.anatomical_structure
DN
dominant negative

TNFR
tumour necrosis factor receptor

NF-κB
nuclear factor κB

Signal transduction
PI3K
phosphoinositide 3-kinase

Signal Transduction
Bone mass
medicine.medical_specialty
ER
oestrogen receptor

BMD
bone mineral density

Biophysics
DGBP
digeranyl bisphosphonate

CVD
cardiovascular disease

ERK
extracellular-signal-regulated kinase

GGPP
geranylgeranyl pyrophosphate

Bone and Bones
S4
osteogenesis
statins
RANKL
RANK ligand

ZGA
zaragozic acid

Internal medicine
Elderly population
medicine
Animals
Humans
Molecular Biology
osteoclastogenesis
GGPPs
GGPP synthase

GR
glucocorticoid receptor

Osteoblasts
ALP
alkaline phosphatase

business.industry
Cell Biology
medicine.disease
BMP-2
bone morphogenetic protein-2

osteoporosis
lcsh:QH501-531
Endocrinology
OPG
osteoprotegerin

RANK
receptor activator of NF-κB

Hydroxymethylglutaryl-CoA Reductase Inhibitors
business
MAPK
mitogen-activated protein kinase
Zdroj: Bioscience Reports, Vol 32, Iss 6 (2012)
Bioscience Reports
ISSN: 1573-4935
0144-8463
DOI: 10.1042/bsr20110118
Popis: Osteoporosis is a common disease in the elderly population. The progress of this disease results in the reduction of bone mass and can increase the incidence of fractures. Drugs presently used clinically can block the aggravation of this disease. However, these drugs cannot increase the bone mass and may result in certain side effects. Statins, also known as HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase inhibitors, have been widely prescribed for CVD (cardiovascular disease) for decades. Nonetheless, several studies have demonstrated that statins exert bone anabolic effect and may be helpful for the treatment of osteoporosis. Several experiments have analysed the mechanisms of bone anabolism regulated by statins. In the present paper, we review the mechanisms of promoting osteogenesis, suppressing osteoblast apoptosis and inhibiting osteoclastogenesis.
Databáze: OpenAIRE